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A series of N-substituted-3-(napthalen-2-yl)-5-substituted phenyl-4,5-dihydropyrazole-1-carbothioamide 
derivatives (4a-n) were synthesized with the view of structural requirements of pharmacophore for 
potential anticonvulsant agents. The synthesized compounds were assayed intraperitoneally (i.p.) and 
subcutaneously (s.c.) in mice against seizures induced by MES and scPTZ methods, respectively.
Neurologic deficit was evaluated by rotarod method. Among the tested compounds, 4g, 4i, 4j and 4n 
emerged as the most active molecule in the MES model at a dose of 30 mg/kg at 0.5h comparable 
to standardscarbamazepine and phenytoin. In the scPTZ test,4e and 4l were found to be most active 
compounds at the lowest dose of 30 mg/kg at 0.5h, in the management of the convulsive disorder. 
Molecular docking studies of the titled compounds were also donewith 3D crystal structure of human 
cytosolic branched chain amino transferase (hBCATc) enzyme and compound 4e was found to have five 
hydrogen bond interactions with the most important active site residues.In neurotoxicity studies, except 
compounds 4b, 4c, 4h and 4k, rest of the compounds showed no sign of toxicity. 
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INTRODUCTION
Epilepsy is a collective term for brain function 
disorders that are characterized by the periodic and 
unpredictable occurrence of seizures. Epilepsies are 
common and frequently devastating, affecting around 
1-2% of the world population (Thakur et al., 2011). With 
available marketed antiepileptic drugs (AEDs) complete 
control of seizures is not achieved till date and also these 
drugs are associated with a wide range of side effects 
(Desaubry et al., 1995).
Recent AEDs like lamotrigine, tiagabine, felbamate, 
pregabalin, stiripentol and topiramate are effective 
toward only 60-80% of patients but these drugs are also 
associated with undesirable side effects, such as headache, 
nausea, anorexia, ataxia, hepatotoxicity, drowsiness, 
gastrointestinal disturbance,gingival hyperplasia and 
hirsutism (Malik, Bahare, Khan, 2013). Therefore, 
valproic acid and carbamazepine, first generation drugs are 
still widely used. Because of limitations with conventional 
AEDs, the need for developing newer agents for epilepsies 
is need of the millennium.Every year March 26 is 
celebrated as Purple Day to raise awareness of epilepsy. 
Pyrazoles and their reduced forms, pyrazolines, 
are nitrogen-containing heterocyclic compounds 
(Beyhan et al . ,  2017). Among all, 2-pyrazolines 
(4,5-dihydropyrazole) continue to be the most promising 
structural unit for various synthetic molecules in 
respect of the highly potential pharmacological profile 
(Motyan et al., 2016). Derivatives containing the 
2-pyrazoline moiety have been reported to have diverse 
biological activities such as antimalarial, antimicrobial, 
antituberculosis, antioxidant, anti-inflammatory, anti-
cancer, anti-microbial, anti-parasitary, antidepressive 
and anticonvulsant properties (Karad et al., 2016). 
Many researchers have reported various routes for their 
synthesis; the most common one is by condensation 
of α,β-unsaturated carbonyl compound with hydrazine 
derivatives (Miguel et al., 2016).
A pharmacophoric model essential for good 
anticonvulsant property was proposed (Dimmock et al., 
1995; Dimmock, Vashishtha, Stables, 2000). According 
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to this model, an anticonvulsant compound should have 
at least one aryl binding site with the hydrophobic group, 
electron donor atoms, hydrogen bonding domain and 
hydrogen binding site in it.
Docking studies have been carried out in order to 
investigate the interactions (ALA 314, THR 313, LYS 202, 
TYR 141, ARG 143 & PHE 75) at the molecular level that 
govern the recognition and binding of synthesized ligands 
to the human cytosolic branched chain amino transferase 
(hBCATc).The hBCATc helps in catalyzing the transfer 
of an amino group from branched chain amino acids to 
α-ketoglutarate and leads to the synthesis of glutamate 
in CNS (Hu et al., 2006). The inhibition of this hBCATc 
in the brain can reduce the release of glutamate during 
excitation in neuronal tissues. Hence, the inhibition 
of glutamate release is useful for the treatment of the 
neurodegenerative disorder such as epilepsy.
We hereby described the synthesis, characterization, 
dockingstudy and anticonvulsant evaluation of 
N-substituted-3-(napthalen-2-yl)-5-substitutedphenyl-
4,5-dihydropyrazole-1-carbothioamide derivatives (4a-n) 
using MES and scPTZ method. Neurotoxicity studies were 
also done to explore the toxicity. 
MATERIAL AND METHODS
All the chemicals used in the synthesis were 
procured from E. Merck and SD Fine-Chem Limited. Thin 
layer chromatography (TLC) was performed on Silica gel 
60 F254 TLC aluminum sheets (Merck) using toluene/
ethyl acetate/formic acid (5:4:1) and benzene/acetone (9:1) 
as a solvent system. The melting points were recorded 
in open capillaries using Hicon melting point apparatus 
(Hicon, India) and are uncorrected. FT-IR spectra were 
recorded in KBr disks using Shimadzu affinity-1(Model 
number 8400S).1H NMR spectra were recorded in CDCl3 
on Bruker Avance on 300 MHz. Elemental analysis for 
CHN was within ±0.4% of the theoretical values. PTZ was 
procured from Shrenik Pharma Ltd. (Mumbai). Anhydrous 
sodium sulfate was used as the drying agent.
Preparation of alkyl and aryl isothiocyanates 
(1a-d)
The alkyl and aryl isothiocyanates (1a-d) were 
prepared as per standard procedure (Furniss et al., 1998).
General synthesis of chalcones (2a-e)
A mixture of equimolar portions of appropriate 
aromatic aldehydes (10 mmol) and 2-acetyl naphthalene 
(10 mmol) was dissolved in 20 mL of ethanol and stirred for 
30 minutes at 5 oC. To the reaction mixture, 10 mL of 10% 
aqueous solution of sodium hydroxide was slowly added 
dropwise using a funnel. The mixture was again stirred for 
2 h keeping the temperature below 10oC and was kept at 
room temperature overnight. The resulting precipitates were 
collected by suction filtration, washed with ice-cold water, 
dried and recrystallized from absolute ethanol.
General synthesis of pyrazoline derivatives (3a-e)
The chalcone (2a-e) was dissolved in 20 mL of 
ethanol and 98% of hydrazine monohydrate (4 mL) 
was added dropwise with stirring. This mixture was 
stirred further for 1 hour. The precipitates formed were 
collected and recrystallized from absolute ethanol to 
obtain (3a-e). 
Synthesis of target compounds (4a-n)
A mixture of compounds (3a-e, 0.01 mol) and 
alkyl/aryl isothiocyanates (0.01 mol, 1a-d) in 20 mL of 
absolute ethanol was refluxed for 4 hours to obtain the 
product (4a-n). The product obtained was purified and 
recrystallized from appropriate solvent.
5-(4-Bromophenyl)-N-cyclohexyl-3-(naphthalen-2-yl)-
4,5-dihydropyrazole-1-carbothio amide (4a)
Sand yellow (amorphous). m.p.: 144-148oC; IR 
(KBr, cm-1): 3461 (NH), 1578 (C=N), 1342 (C=S); 1H 
NMR (300 MHz, CDCl3): δ 7.05-7.91 (m, 11H, Ar-H), 
4.17 (dd, 1H, HA, JAB = 17.73 Hz, JAX = 8.06 Hz), 4.24 
(dd, 1H, HB, JBA = 17.73, JBX = 4.27 Hz), 4.63 (dd, 1H, 
HX, JXA = 8.07 Hz, JXB = 4.25 Hz), 9.12 (s, 1H, NH, D2O 
exchangeable), 1.35-3.46 (m, 11H, CH2-cyclohexane); 
Anal. calcd. for C26H26BrN3S: C, 63.41; H, 5.32; N, 8.53; 
Found: C, 63.45; H, 5.34; N, 8.56%.
N-cyclohexyl-3-(naphthalen-2-yl)-5-phenyl-4,5-
dihydropyrazole-1-carbothioamide (4b)
Greenish-yellow (crystals).m.p.: 170-173oC; IR 
(KBr, cm-1): 3459 (NH), 1572 (C=N), 1362 (C=S); 
1H NMR (300 MHz, CDCl3): δ 6.95-7.84 (m, 12H, 
Ar-H), 4.25 (dd, 1H, HA, JAB = 17.61 Hz, JAX = 8.03 
Hz), 4.32 (dd, 1H, HB, JBA = 17.61 Hz, JBX = 4.25 Hz), 
4.65 (dd, 1H, HX, JXA = 8.05 Hz, JXB = 4.27 Hz), 9.24 
(s, 1H, NH, D2O exchangeable), 1.38-3.69 (m, 11H, 
CH2-cyclohexane);Anal. calcd. for C26H27N3S: C, 
75.51; H, 6.58; N, 10.16; Found: C, 75.49; H, 6.60; 
N, 10.19%.
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5-(4-Chlorophenyl)-N-cyclohexyl-3-(naphthalen-2-yl)-
4,5-dihydropyrazole-1-carbothio amide (4c)
Brownish yellow (amorphous). m.p.: 132-134oC; 
IR (KBr, cm-1): 3360 (NH), 1570 (C=N), 1356 (C=S); 1H 
NMR (300 MHz, CDCl3): δ 7.12-7.99 (m, 11H, Ar-H), 
4.23 (dd, 1H, HA, JAB = 17.62 Hz, JAX = 8.05 Hz), 4.26 
(dd, 1H, HB, JBA = 17.62 Hz, JBX = 4.27 Hz), 4.67 (dd, 1H, 
HX, JXA = 8.06 Hz, JXB = 4.26 Hz), 9.21 (s, 1H, NH, D2O 
exchangeable), 1.29-3.56 (m, 11H, CH2-cyclohexane); 
Anal. calcd. for C26H26ClN3S: C, 69.70; H, 5.85; N, 9.38; 
Found: C, 69.73; H, 5.82; N, 9.40%.
N-cyclohexyl-3-(naphthalen-2-yl)-5-(2-nitrophenyl)-
4,5-dihydropyrazole-1-carbothioamide (4d)
Ochre (amorphous). m.p.: 120-125oC; IR (KBr, cm-
1): 3359 (NH), 1586 (C=N), 1364 (C=S), 1H NMR (300 
MHz, DMSO-d6): δ 7.02-8.05 (m, 11H, Ar-H), 4.45 (dd, 
1H, HA, JAB = 17.74 Hz, JAX = 7.96 Hz), 4.45 (dd, 1H, HB, 
JBA = 17.74 Hz, JBX = 4.32 Hz), 4.91 (dd, 1H, HX, JXA = 8.06 
Hz, JBX = 4.33 Hz), 9.22 (s, 1H, NH, D2O exchangeable), 
1.32-3.69 (m, 11H, CH2-cyclohexane); Anal. calcd. for 
C26H26N4O2S: C, 68.10; H, 5.71; N, 12.22; Found: C, 
68.12; H, 5.75; N, 12.20%.
N-cyclohexyl-3-(naphthalen-2-yl)-5-(4-nitrophenyl)-
4,5-dihydropyrazole-1-carbothioamide (4e)
Mustard (amorphous). m.p.: 116-119oC; IR (KBr, 
cm-1): 3366 (NH), 1588 (C=N), 1347 (C=S); 1H NMR (300 
MHz, CDCl3): δ 7.12-8.04 (m, 11H, Ar-H), 4.24 (dd, 1H, 
HA, JAB = 17.71 Hz, JAX = 8.26 Hz), 4.28 (dd, 1H, HB, JBA 
= 17.71 Hz, JBX = 4.37 Hz), 4.77 (dd, 1H, HX, JXA = 8.24 
Hz, JXB = 4.35 Hz), 9.13 (s, 1H, NH, D2O exchangeable), 
1.29-3.66 (m, 11H, CH2-cyclohexane); Anal. calcd. for 
C26H26N4O2S: C, 68.10; H, 5.71; N, 12.22; Found: C, 
68.13; H, 5.72; N, 12.25%.
5-(4-Bromophenyl)-3-(naphthalen-2-yl)-N-(p-tolyl)-4,5-
dihydropyrazole-1-carbothioamide (4f)
Brownish white (amorphous). m.p.: 140-145oC; IR 
(KBr, cm-1): 3347 (NH), 1581 (C=N), 1355 (C=S), 1H NMR 
(300 MHz, CDCl3): δ 7.07-7.94 (m, 15H, Ar-H), 4.16 (dd, 
1H, HA, JAB = 17.69 Hz, JAX = 8.04 Hz), 4.31 (dd, 1H, HB, 
JBA = 17.69 Hz, JBX = 4.29 Hz), 4.68 (dd, 1H, HX, JXA = 8.06 
Hz, JXB = 4.27 Hz), 9.16 (s, 1H, NH, D2O exchangeable), 
2.21 (s, 3H, CH3); Anal. calcd. for C27H22BrN3S: C, 64.80; 
H, 4.43; N, 8.40; Found: C, 64.77; H, 4.47; N, 8.42%.
3-(Naphthalen-2-yl)-5-phenyl-N-(p-tolyl)-4,5-
dihydropyrazole-1-carbothioamide (4g)
Yellowish–green (crystals). m.p.: 96-98oC; IR (KBr, 
cm-1): 3400 (NH), 1561 (C=N), 1365 (C=S); 1H NMR (300 
MHz, CDCl3): δ 7.10-7.94 (m, 16H, Ar-H), 4.16 (dd, 1H, 
HA, JAB = 17.65 Hz, JAX = 8.22 Hz), 4.32 (dd, 1H, HB, JBA = 
17.65 Hz, JBX = 4.27 Hz), 4.65 (dd, 1H, HX, JXA = 8.21 Hz, 
JXB = 4.27 Hz), 9.13 (s, 1H, NH, D2O exchangeable), 2.18 
(s, 3H, CH3); Anal. calcd. for C27H23N3S: C, 76.93; H, 5.50; 
N, 9.97; Found: C, 76.98; H, 5.47; N, 9.99%.
3-(Naphthalen-2-yl)-5-(2-nitrophenyl)-N-(p-tolyl)-4,5-
dihydropyrazole-1-carbothioamide (4h)
Light yellow (amorphous). m.p: 138-140oC; IR 
(KBr, cm-1): 3349 (NH), 1564 (C=N), 1350 (C=S); 1H 
NMR (300 MHz, CDCl3): δ 7.04-8.05 (m, 15H, Ar-H), 
4.37 (dd, 1H, HA, JAB = 16.29 Hz, JAX = 8.19 Hz), 4.43 
(dd, 1H, HB, JBA = 16.29 Hz, JBX = 4.29 Hz), 4.90 (dd, 
1H, HX, JXA = 8.20 Hz, JXB = 4.27 Hz), 9.12 (s, 1H, NH, 
D2O exchangeable), 2.17 (s, 3H, CH3); Anal. calcd. for 
C27H22N4O2S: C, 69.51; H, 4.75; N, 12.01; Found: C, 
69.57; H, 4.72; N, 12.03%.
3-(Naphthalen-2-yl)-5-(2-nitrophenyl)-N-phenyl-4,5-
dihydropyrazole-1-carbothioamide (4i)
Pale to dark yellow (amorphous). m.p.:150-154oC; 
IR (KBr, cm-1): 3339 (NH), 1579 (C=N), 1361 (C=S); 1H 
NMR (300 MHz, DMSO-d6): δ 6.94-8.07 (m, 15H, Ar-
H), 4.36 (dd, 1H, HA, JAB = 16.28 Hz, JAX = 8.20 Hz), 4.43 
(dd, 1H, HB, JBA = 16.28 Hz, JBX = 4.28 Hz), 4.90 (dd, 1H, 
HX, JXA = 8.18 Hz, JXB = 4.27 Hz), 9.12 (s, 1H, NH, D2O 
exchangeable); Anal. calcd. for C26H20N4O2S: C, 69.01; 
H, 4.45; N, 12.38; Found: C, 69.03; H, 4.41; N, 12.35%.
5-(4-Chlorophenyl)-N-methyl-3-(naphthalen-2-yl)-4,5-
dihydro-1H-pyrazole-1-carbothioamide (4j)
Skin colored (crystals). m.p.: 124-126oC; IR 
(KBr, cm-1): 3303 (NH), 1566 (C=N), 1349 (C=S); 1H 
NMR (300 MHz, CDCl3): δ 7.22-7.94 (m, 11H, Ar-H), 
4.19 (dd, 1H, HA, JAB = 17.69 Hz, JAX = 8.19 Hz), 4.25 
(dd, 1H, HB, JBA = 17.69 Hz, JBX = 4.31 Hz), 4.66 (dd, 
1H, HX, JXA = 8.20 Hz, JXB = 4.29 Hz), 9.19 (s, 1H, NH, 
D2O exchangeable), 2.44 (s, 3H, CH3); Anal. calcd. for 
C21H18ClN3S: C, 66.39; H, 4.78; N, 11.06; Found: C, 
66.44; H, 4.76; N, 11.09%.
N-methyl-3-(naphthalen-2-yl)-5-(4-nitrophenyl)-4,5-
dihydropyrazole-1-carbothioamide (4k)
Dark yellow (amorphous). m.p.: 110-115oC; IR 
(KBr, cm-1): 3386 (NH), 1580 (C=N), 1353 (C=S); 1H 
NMR (300 MHz, CDCl3): δ 7.19-8.03 (m, 11H, Ar-H), 
4.28 (dd, 1H, HA, JAB = 17.59 Hz, JAX = 8.06 Hz), 4.28 
(dd, 1H, HB, JBA = 17.59 Hz, JBX = 4.27 Hz), 4.76 (dd, 
1H, HX, JXA = 8.07 Hz, JXB = 4.29 Hz), 9.21 (s, 1H, NH, 
D2O exchangeable), 2.39 (s, 3H, CH3); Anal. calcd. for 
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C21H18N4O2S: C, 64.60; H, 4.65; N, 14.35; Found: C, 
64.58; H, 4.66; N, 14.38%.
5-(4-Bromophenyl)-N-methyl-3-(naphthalen-2-yl)-4,5-
dihydropyrazole-1-carbothioamide (4l)
Light brown (amorphous). m.p.: 160-164oC; IR (KBr, 
cm-1): 3412 (NH), 1575 (C=N), 1370 (C=S); 1H NMR (300 
MHz, CDCl3): δ 6.89-7.94 (m, 11H, Ar-H), 4.23 (dd, 1H, 
HA, JAB = 17.67 Hz, JAX = 8.16 Hz), 4.27 (dd, 1H, HB, JBA = 
17.67 Hz, JBX = 4.27 Hz), 4.66 (dd, 1H, HX, JXA = 8.17 Hz, 
JXB = 4.28 Hz), 9.23 (s, 1H, NH, D2O exchangeable), 2.42 (s, 
3H, CH3); Anal. calcd. for C21H18BrN3S: C, 59.44; H, 4.28; 
N, 9.90; Found: C, 59.51; H, 4.26; N, 9.95%.
N-methyl-3-(naphthalen-2-yl)-5-(2-nitrophenyl)-4,5-
dihydropyrazole-1-carbothioamide (4m)
Pale yellow (amorphous). m.p.: 146-148oC; IR 
(KBr, cm-1): 3378 (NH), 1571 (C=N), 1348 (C=S); 1H 
NMR (300 MHz, CDCl3): δ 7.12-8.05 (m, 11H, Ar-H), 
4.44 (d, 1H, J = 8.19 Hz), 4.44 (d, 1H, 4.28 Hz), 4.90 
(dd, 1H, HX, JXA = 8.18 Hz, JXB = 4.17 Hz), 9.25 (s, 1H, 
NH, D2O exchangeable), 2.397 (s, 3H, CH3); Anal. calcd. 
for C21H18N4O2S: C, 64.60; H, 4.65; N, 14.35; Found: C, 
64.58; H, 4.67; N, 14.39%.
5-(4-Bromophenyl)-N-ethyl-3-(naphthalen-2-yl)-4,5-
dihydropyrazole-1-carbothioamide (4n)
Dark brown (amorphous). m.p.: 89-92oC; IR 
(KBr,cm-1): 3232 (NH), 1577 (C=N), 1373 (C=S); 1H 
NMR (300 MHz, CDCl3): δ 6.85-7.99 (m, 11H, Ar-H), 
4.24 (dd, 1H, HA, JAB = 17.65 Hz, JAX = 8.06 Hz), 4.27 
(dd, 1H, HB, JBA = 17.65 Hz, JBX = 4.27 Hz), 4.66 (dd, 1H, 
HX, JXA = 8.07 Hz, JXB = 4.28 Hz), 9.21 (s, 1H, NH, D2O 
exchangeable), 1.22 (triplet, 3H, CH2CH3), 3.19 (quartet, 
2H, CH2 CH3); Anal. calcd. for C22H20BrN3S: C, 60.27; H, 
4.60; N, 9.59; Found: C, 60.33; H, 4.62; N, 9.56%.
Molecular docking
The molecular docking study was carried out in 
order to assess their interaction and binding modes with 
target receptor and good biological activity using Glide 
extra precision (XP) Maestro 10.1 Schrodinger, running 
on Linux 64 operating system (Schrodinger, 2016). The 
2D structure of synthesized compounds was generated 
and then converted to their respective 3D structures with 
the use of Ligprep. The X-ray crystal structure of 2A1H 
(PDB ID) was downloaded from Protein Data Bank solved 
at a resolution of 1.8 Å. The protein was prepared using 
the protein preparation wizard and the grid was generated 
for co-crystal ligand. The water residues beyond 5 Å 
were eliminated. The protein was optimized by assigning 
H-bonds and minimization at OPLS 2005 force field. 
Molecular docking studies mainly involve selection and 
preparation of appropriate protein, grid generation, ligand 
preparation followed by docking & its analysis. The docking 
score, hydrogen bonds and pi-pi interactions formed with 
the enclosed amino acids were used to conclude their 
binding affinities and proper alignment of these compounds 
at the active site of the receptor. Binding energy estimation 
can be used to calculate ligand binding energies and strain of 
ligand energies for a set of ligand on a single receptor using 
the Prime molecular mechanics-generalized born surface 
area (MM-GBSA) method, Maestro 10.1. The ligands and 
the receptors were prepared by using LigPrep and Protein 
preparation wizard. The binding poses for compound were 
analyzed by examining their free energy scores.
Pharmacology
The pharmacological testing of all the final 
compounds was performed according to the standard 
protocol given by epilepsy branch of the National Institute 
of Neurological Disorders and Stroke (NINDS), NIH, 
Rockville, MD 20892, USA following the protocol adopted 
by the Antiepileptic Drug Development (ADD) program. 
The investigations were conducted on albino mice 
(20-24 g) of either sex. The albino mice were kept under 
standard conditions at an ambient temperature of 25±2 °C. 
Food and water were withdrawn prior to the experiment. 
The synthesized compounds were tested against the 
standard drugs phenytoin and carbamazepine at a dose of 
30, 100 and 300 mg/kg i.p. The solution of standard drugs 
and test compounds were prepared in propylene glycol. 
Maximal electroshock seizure Test (MES Test) 
In this test (Krall et al., 1978), mice were pre-
screened 24 hours before by delivering maximal 
electroshock (50 mA; 60 Hz and 0.2 s duration) by means 
of corneal electrodes. A drop of 0.9% sodium chloride was 
instilled in each eye prior to the application of electrodes 
in order to prevent the death of the animal. Test solutions 
of all compounds were dosed intraperitoneally 30 min 
prior to testing. Abolition of hind limb tonic extensor 
component of the seizure in half or more of the animals is 
defined as protection.
Sub-cutaneous Pentylenetetrazole Test (scPTZ Test)
The scPTZ test (Swinyard et al., 1989) utilized a 
dose of pentylenetetrazole 85 mg/kg s.c. This produced 
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clonic seizure lasting for a period of at least 5 seconds. 
The test compounds were administered at the three graded 
doses of 30, 100 and 300 mg/kg i.p. At the anticipated time, 
the convulsant was administered subcutaneously. Animals 
were observed over a 30 min period. The absence of clonic 
spasm in half or more of the animals in the observed time 
period indicated a compounds ability to abolish the effect 
of pentylenetetrazole on seizure threshold.
Neurotoxicity study
Rotarod Test: The minimal motor impairment 
was measured in mice by rotarod test (Dunham, Miya, 
Edwards, 1957). The mice were trained to stay on an 
accelerating rotarod of diameter 3.2 cm that rotates at 10 
rpm. Neurotoxicity was indicated by the inability of the 
animal to maintain equilibrium on the rod for at least one 
minute in each of the three trials. The dose at which 50% 
of the animals enabled to balance themselves and full off 
the rotating rod was determined.
RESULTS AND DISCUSSION
Chemistry
The present work is focused on the synthesis, 
characterization,  molecular  docking study and 
anticonvulsant evaluation of N-substituted-3-(napthalen-
2-yl)-5-substituted phenyl-4,5-dihydropyrazole-1-
carbothioamide derivatives. A series of 15 compounds 
were synthesized as per the synthetic route described 
in Scheme 1. The physicochemical parameters of the 
synthesized pyrazoline derivatives are given in Table I.
The synthesized compounds were characterized by 
elemental and spectral analysis (FT-IR and 1H NMR). 
Characterization was done after crystallization from 
appropriate solvents. The synthesized compounds 
were found to have N–H, C=N and C=S stretching 
bands in the region of 3466-3232, 1588-1570 and 
1373-1347 cm_1, respectively, in the IR spectra.The 
1H NMR spectra of compounds were recorded in CDCl3/
DMSO-d6 solvent using TMS as an internal standard. 
In 1H NMR, these compounds exhibited multiplets for 
Ar-H in the regions of 6.859-8.076 ppm, a singlet in the 
region of 9.198-9.242 ppm for (N–H).The CH2 protons 
of the pyrazoline ring were found to resonate as a pair 
of doublets at 4.162-4.456 ppm (HA), 4.242-4.454 ppm 
(HB). Furthermore, the CH (HX) proton appeared as 
doublets at 4.631-4.916 ppm due to vicinal coupling 
with the two magnetically non-equivalent protons of 
the methylene group at position 4 of the pyrazoline 
ring (JAB: 17.65-18.40 Hz, JAX: 2.90-8.01 Hz, JBX: 
11.07-13.28 Hz). 
Pharmacological evaluation
The pharmacological evaluation for anticonvulsant 
and neurotoxicity was performed as per the standard 
methods proposed by NIH anticonvulsant drug 
development (ADD) program (Stables et al., 1978), via the 
anticonvulsant screening project (ASP). The evaluation 
included the maximal electroshock (MES), subcutaneous 
pentylenetetrazole (scPTZ) and neurotoxicity (Tox). In 
the testing, the compounds (4a-n) were administered 
i.p. into mice at dose of 30,100 and 300 mg/kg and 
observations were taken at two different intervals (0.5 h 
and 4 h). Neurotoxicity was measured by rotarod test. The 
results are shown in Table II. The results revealed that the 
compounds 4a, 4d, 4e, 4g, 4i, 4j, 4l and 4n possessed 
good anticonvulsant activity against the MES model at 
30 mg/kg at time period of 0.5 h indicating their good 
ability to prevent seizure spread.Whereas compound 4a, 
4e, 4f, 4g, 4i 4j and 4n showed anticonvulsant activity 
against standards carbamazepine and phenytoin at a dose 
of 100 mg/kg at the time period of 0.5 h, indicating their 
ability to prevent seizure spread at relatively higher dose. 
At a dose level of 300 mg/kg, 4g and 4j showed good 
anticonvulsant activity at time period of 0.5 h concluding 
that these compounds have rapid onset of action at 
higher dose level. Compounds 4i and 4j showed good 
anticonvulsant behavior at a dose level of 30 mg/kg even 
at time period of 4h, indicating their long duration of action 
at a lower dose. Among all, compounds 4g, 4i, 4j and 4n 
showed full protection at a dose of 100 mg/kg at the time 
period of 0.5 h and can be further explored to know the 
mechanism of action.
In the scPTZ test, compound 4e and 4l showed good 
inhibition of clonic and tonic seizures at 30 mg/kg at 0.5h. 
However, some level of inhibition was observed with 4e, 
4j and 4n at a higher dose of 100 mg/kg at 0.5 h duration. 
Compound 4i was inactive at 0.5 h but showed inhibition 
of seizure at 30 mg/kg at a time period of 4 h, showing 
that this compound has long duration of action at a lower 
dose. Rest of the compounds in MES and scPTZ test were 
either inactive or didn’t show any significant results. In 
neurotoxicity screening, the results indicated absence of 
neurotoxicity in most of the tested compounds at 30, 100 
and 300 mg/kg. Only compound 4b, 4c, 4h and 4k were 
found neurotoxic at a higher dose of 300 mg/kg.
On structure correlation of compounds with 
anticonvulsant activity showed that compounds substituted 
with electron-withdrawing group (NO2, chloro or bromo) 
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SCHEME 1 - Reagents and conditions: (a) EtOH, 0-5 °C;  (b) NH2NH2.2H2O, Room temp;  (c) alkyl/aryl/NCS
at second and fourth position of hydrophobic aryl ring with 
hexyl, phenyl, methyl or ethyl substitution at distal aryl 
ring were found responsible for excellent anticonvulsant 
activity. 
Lipophilicity
The Clog P values are the indicative of the importance 
of lipophilicity as electronic properties of substituents 
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TABLE I - Physicochemical parameters of the synthesized compounds (4a-n)
Compd. no. R R1
Molecular 
Formulaa Mol. Wt. Yield (%) Rf
b Clog Pc Rm
4a 4-Br
 
C26H26BrN3S 492.47 85 0.65 7.28 -0.22
4b H
 
C26H27N3S 413.58 80 0.80 6.42 -0.39
4c 4-Cl
 
C26H26ClN3S 448.02 80 0.73 7.13 -0.69
4d 2-NO2
 
C26H26N4O2S 458.58 86 0.71 6.08 -0.39
4e 4-NO2
 
C26H26N4O2S 458.58 84 0.80 6.16 -0.69
4f 4-Br CH3
 
C27H22BrN3S 500.45 82 0.82 7.18 -0.39
4g H CH3
 
C27H23N3S 421.56  84 0.72 6.32 -0.69
4h 2-NO2 CH3
 
C27H22N4O2S 466.55 83 0.67 5.98 -0.22
4i 2-NO2
 
C26H20N4O2S 452.53 81 0.62 5.49 -0.22
4j 4-Cl CH3 C21H18ClN3S 379.91 79 0.85 5.10 -0.69
4k 4-NO2 CH3 C21H18N4O2S 390.46 84 0.74 4.13 -0.39
4l 4-Br CH3 C21H18BrN3S 424.36 80 0.81 5.25 -0.69
4m 2-NO2 CH3 C21H18N4O2S 390.46 76 0.70 4.05 -0.39
4n 4-Br CH2CH3 C22H20BrN3S 438.38 80 0.80 5.78 -0.69
aElemental analysis for C,H, N were within ±0.4% of the theoretical values. bSolvent system used toluene:acetone (8:2). 
cClog P: calculated using software Chem. Draw ultra 12.0. Rm values were calculated by the formula Rm=log[(1/Rf-1)] 
on the activity of these compounds. The relatively 
favorable anticonvulsant activity for all the compounds 
displayed Clog P values 4.39-7.28. The lipophilicity of 
the compounds shown by Rm value was found to be in the 
range of -0.22 to -1.00, which can be considered to be 
optimum lipophilicity for the congeners that act on the 
central nervous system are summarized in Table I.
Molecular docking
The molecular docking studies were performed 
to establish the binding ability of the synthesized 
compounds to the human cytosolic branched chain amino 
transferase (hBCATc) (Gotoet al., 2005). The docking 
scores and binding free energy of all the compounds 
and co-crystal ligand (gabapentin) with the active site 
of human cytosolic branched chain amino transferase 
(hBCATc) were summarized in Table III. The results of 
docking studies showed that thirteen compounds (4a-
n) exhibited higher docking score than that of co-crystal 
(gabapentin)suggesting that the synthesized compounds 
(4a-n) displayed better interaction with hBCATc.The 
B. Nusrat, N. Siddiqui, M. Sahu, M. J. Naim, M. S.Yar, R. Ali, O. Alam
Braz. J. Pharm. Sci. 2019;55:e00249Page 8 / 11
2D ligand interaction diagram of 4e was represented in 
Figure 1(a).
TABLE III - Docking scores and binding free energy of 
compounds (4a-n)
Compounds Docking Scores Binding Free Energy (Kcal/mol)
4e
4b
4j
4f
4g
4i
4l
4a
4c
4n
4k
4h
4d
4m
Gabapentin
-4.28
-4.27
-4.01
-3.74
-3.69
-3.65
-3.61
-3.59
-3.46
-3.44
-3.27
-2.59
-2.46
-2.13
-2.51
-61.44
-63.13
-55.17
-43.21
-69.62
-71.43
-65.21
-61.30
-68.71
-62.80
-55.61
-67.47
-64.18
-62.32
-40.24
TABLE II - Anticonvulsant activity and neurotoxicity screening of compounds (4a-n).
Test MES scPTZ Tox
Time 0.5 h 4h 0.5 h 4 h 0.5h 4 h
Dose 
(mg/kg) 30 100 300 30 100 300 30 100 300 30 100 300 30 100 300 30 100 300
4a 2/4 2/4 0/4 1/4 1/4 0/4 1/4 x x x x x _ _ _ _ _ _
4b 1/4 0/4 0/4 0/4 0/4 0/4  x x x x x x _ _ _ _ _ 4/4
4c 1/4 1/4 1/4 0/4 1/4 1/4  x x x x x x _ _ 2/4 _ _ _
4d 2/4 1/4 1/4 1/4 0/4 0/4 1/4 x x x x x _ _ _ _ _ _
4e 2/4 3/4 1/4 0/4 1/4 0/4 3/4 2/4 x x x x _ _ _ _ _ _
4f 1/4 2/4 1/4 1/4 0/4 0/4 x 1/4 x x x x _ _ _ _ _ _
4g 2/4 4/4 2/4 1/4 1/4 0/4 1/4 1/4 x x x x _ _ _ _ _ _
4h 0/4 1/4 0/4 1/4 1/4 0/4  x x x x x x _ _ _ _ _ 1/4
4i 3/4 4/4 1/4 2/4 0/4 0/4 0/4 x x 2/4 x x _ _ _ _ _ _
4j 3/4 4/4 2/4 2/4 1/4 0/4 1/4 2/4 x 1/4 x x _ _ _ _ _ _
4k 1/4 0/4 1/4 0/4 0/4 0/4  x x x x x x _ _ 1/4 _ _ 1/4
4l 2/4 1/4 1/4 1/4 1/4 0/4 3/4 x x x x x _ _ _ _ _ _
4m 1/4 1/4 1/4 0/4 0/4 0/4  x x x x x x _ _ _ _ _ _
4n 2/4 4/4 1/4 1/4 1/4 0/4 x 2/4 x x x x _ _ _ _ _ _
Phenytoin 4/4 4/4 4/4 4/4 4/4 4/4 0/0 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 4/4 4/4
Carbamazepine 4/4 4/4 4/4 0/4 4/4 4/4 0/4 0/4 4/4 0/4 4/4 4/4 0/4 0/4 4/4 0/4 0/4 0/4
MES: Maximal electroshock seizure test (number of animal protected/number of animal tested). scPTZ: subcutaneous 
pentylenetetrazole test (number of animal protected/number of animal tested). Tox: rotarod test (number of animal exhibiting 
toxicity/number of animal tested). Solvent used: propylene glycol (0.1 mL, i.p.). (-): indicates absence of neurotoxicity. (x): 
indicates compounds not tested.
The most potent compound 4e fitted nicely into the 
hBCATc enzyme making five hydrogen bond interactions 
with the most important active site residues ARG 143(N....
HN), LYS 202 (O....HN), ALA 314 (O....HN), THR 313 
(O....HN) and TYR 141 (O....HO) Figure 1(b). The PHE 75 
residue makes pi-pi interaction with the p-nitro phenyl ring 
in compound 4e at distances 5.40 Å (phenyl....phenyl). The 
NH of thiamide group in 4b seems to have an important 
role in strong hydrogen bond interaction with THR 240 
(H...OH) as shown in Figure 2(b). Moreover compound 
4b formed a pi-cation interaction with LYS 202 (Phenyl....
H3N+). The current study showed that the presence of nitro 
group at para position of aromatic ring in 4e has significant 
activity and their docking scores. The polar regions in 
catalytic site was found near nitro group and surrounded 
by ARG 99, GLU 76, LYS 202 and GLY 77, which favours 
the interaction of nitro group leads to high docking score. 
A docking study of co-crystal ligand, gabapentin was 
performed which displayed a hydrogen bonding with 
the side chains of THR 240, TYR 141 and backbone of 
THR 313 and ALA 314, depicted in Figure 3(a). The 4e 
and gabapentin has almost same biding mode and both 
the compounds share some common hydrogen bond 
such as THR 313, ALA 314 and TYR 141. The receptor 
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surface view of superimposed structure of gabapentin 
and 4e in the binding site are represented in Figure 3(b).
The molecular docking protocol was validated by re-
docking of the co-crystallized ligand, gabapentin back 
into the same active site of hBCATc and found to have 
almost same interaction. The docking of co-crystal ligand, 
gabapentin against the generated grid showed almost same 
docking mode as compound 4e with RMSD value of 1.7 
and therefore, docking protocol was validated by the 
generated grid.The molecular surface model of compound 
4e is represented in Figure 2. The dG binding energy of 
compounds was found in the range of -43.21 to -71.43 
Kcal/mol for enzyme hBCATc active sites (Table III). All 
the compounds displayed a higher binding free energy 
(dG bind) for hBCATc which indicates that compounds 
have higher selectivity and stability towards hBCATc. 
Whereas, the binding energy of co-crystal ligand was 
found to be -40.24 kcal/mol and less than the synthesized 
compounds (4a-n). 
FIGURE 1 - 2D Ligand interaction of (a) compound 4e (b) compound 4b, using LigPlot.
FIGURE 2 - (a) Docked pose of best ranked docking score of compound 4e (yellow green colour) represented as ball and stick in 
the binding site of hBCATc showing hydrogen bond interaction (yellow dash lines) (b) Docked pose of compound 4b (pink colour)
represented as ball and stick in the binding site of hBCATc showing hydrogen bond interaction (yellow dash lines) and pi-cation 
interaction (green dash lines).
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CONCLUSION
In the present study, new 2-pyrazoline derivatives 
(4a-n) were synthesized and tested for their anticonvulsant 
potential against MES and scPTZ model. In MES model, 
compounds 4g, 4i, 4j and 4n were found most potent among 
all.Furthermore, in the scPTZ test, 4e and 4l were found 
to be most active at the lowest dose of 30 mg/kg which is 
comparable to standards carbamazepine and phenytoin. 
The molecular docking study of the compound 4e was 
also found in favor of biological activity. The molecular 
docking study was performed for the better understanding 
of drug-receptor interactions. Therefore, it can be used as 
a perspective pharmacophore model for the design and to 
illustrate potential activity. The above compounds can be 
considered as strong candidates for future investigations. 
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FIGURE 3 - (a) Docked Pose of co-crystal, gabapentin (yellow colour) represented as ball and stick in the binding site of hBCATc 
showing hydrogen bond interaction (yellow dash lines) (b) A receptor surface of superimpose gabapentin (yellow colour) with 4e 
(yellow green colour) in the binding site of hBCATc.
FIGURE 4 - Surface view of compound 4e. The protein is depicted in the surface view and ligand 4e as ball and stick in the binding 
pocket of hBCATc receptor.
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